Skip to Content

Privacy Notification

We use cookies on our site to analyze traffic, enchance your experience, and provide you with tailored content. For full functionality of this site, you must consent to the use of cookies. For more information or to opt out, visit our privacy policy.

In April 2020, the U.S. Food and Drug Administration (FDA) asked all manufacturers to withdraw ranitidine products from the market after finding extremely high levels of the carcinogen nitrosodimethylamine (NDMA) in the ingredients of ranitidine medications—commonly known by the brand name Zantac.

The FDA confirmed that ranitidine contains unacceptable levels of NDMA and that the amount of NDMA increases when the medication is exposed to higher temperatures. NDMA exposure is safe if limited to 96 nanograms per day. But one tablet of Zantac can contain up to 2.5 to 3 million nanograms of NDMA.

NDMA is toxic—a chemical commonly used to cause cancer in lab rats and as an ingredient in rocket fuel. Drug manufacturers were aware of the risk but said nothing. 

The increased risk of cancer for consumers of Zantac is undeniable, and our team at Keller Lenkner is fighting hard for victims. Although we wish we could reverse our clients’ tragic diagnoses, we are tirelessly fighting to hold the defendants—including brand and generic makers of the heartburn medication—accountable.

Do I qualify for a lawsuit?

Keller Lenkner represents individuals throughout the United States who took Zantac or a generic brand of ranitidine to treat heartburn and were later diagnosed with cancer. The federal Zantac multidistrict litigation consolidates for pretrial purposes lawsuits accusing Pfizer Inc., Sanofi SA, Boehringer Ingelheim Pharmaceuticals Inc., and GlaxoSmithKline LLC—as well as generic makers, distributors, pharmacies, and others in the supply chain—of design defect, failure to warn, and other claims.

If you were diagnosed with cancer after consuming Zantac or generic ranitidine, you may qualify for legal action. We will work to help you obtain justice and compensation.

Contact Us for a Legal Consultation

 

Why work with Keller Lenkner?

Keller Lenkner is honored to help lead litigation in the Zantac federal multidistrict litigation. Partner Ashley Keller chairs the Law & Briefing Committee on behalf of all claimants. Our firm has also filed suits in state courts around the country.

Our team comprises some of the most skilled attorneys in the country. We have litigated matters involving medical devices, pharmaceutical products, and a wide variety of other consumer products. We understand the harm you may have experienced and the seriousness of your claims, and we are committed to providing excellent representation on your behalf.

If you believe you have a claim related to your consumption of Zantac (ranitidine), please contact us.